Compare ACTG & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACTG | AURA |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.9M | 333.4M |
| IPO Year | N/A | N/A |
| Metric | ACTG | AURA |
|---|---|---|
| Price | $4.01 | $5.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | ★ 210.7K | 206.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $127.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $81.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.70 | $4.35 |
| 52 Week High | $4.41 | $8.03 |
| Indicator | ACTG | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 38.69 |
| Support Level | $3.93 | $4.87 |
| Resistance Level | $4.10 | $5.85 |
| Average True Range (ATR) | 0.15 | 0.36 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 48.39 | 14.06 |
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations. It derives revenue from Intellectual Property Operations segment. Geographically, it operates in Americas, Europe, Middle East and Africa, China, India, and Asia-Pacific, excluding China and India.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.